title: Anti-angiogenesis and metastasis: a tumour and stromal cell alliance.
abstract: Tumour progression requires the activation of a tumour and stromal cell-driven angiogenic programme, and the targeting of this process demonstrates an impact on tumour growth and progression. The results of preclinical studies have demonstrated a proinvasive/metastatic effect of antiangiogenic treatments with recent evidence supporting a contribution of the stroma to tumour aggressiveness and the short-term effects of antivascular endothelial growth factor therapy. Furthermore, hypoxia-dependent and -independent factors are considered as driving forces for tumour cell escape by altering both the tumour cells themselves and the stroma. This tumour-stromal cell alliance should be taken into consideration for the development of innovative therapeutic options targeting both tumour components to improve clinical benefits for cancer patients.
authors.affiliation: Tumor Angiogenesis Group, Catalan Institute of Oncology - IDIBELL, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Moserle
authors.forename: O
authors.initials: O
authors.lastname: Casanovas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000378:metabolism; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A